{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:05:56Z","timestamp":1792569956658,"version":"4.5.0"},"reference-count":43,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5,1]]},"abstract":"<jats:p>OBJECTIVE. Budesonide is an inhaled steroid with a strong topical effect but with minimal systemic effects; it has been effectively delivered to animal lungs using surfactant as a vehicle. The purposes of this study were to determine whether early intratracheal instillation of budesonide using surfactant as a vehicle would improve pulmonary status, reduce mortality, and reduce chronic lung disease morbidity.<\/jats:p>\n                  <jats:p>PATIENTS AND METHODS. We conducted a prospective, randomized blind trial in 116 very low birth weight infants (&amp;lt;1500 g) who had severe radiographic respiratory distress syndrome and required mechanical ventilation with fraction of inspired oxygen \u22650.6 shortly after birth: 60 were in the treated group (intratracheal instillation of a mixture of 0.25 mg\/kg of budesonide and 100.00 mg\/kg of survanta, every 8 hours) and 56 were in the control group (100 mg\/kg of survanta only, every 8 hours). The end point assessment was the number of infants who would die or develop chronic lung disease at 36 weeks\u2019 postconceptional age.<\/jats:p>\n                  <jats:p>RESULTS. Infants in the treatment group required significantly lower mean airway pressure on day 1 and day 3 and had significantly lower oxygen index and Pco2 during the first 3 days than infants in the control group. More infants were extubated in the treatment group than controls at 1 and 2 weeks. The combined outcome of deaths or chronic lung disease was significantly lower in the treatment group than in the control group (19 of 60 vs 34 of 56). No clinically significant adverse effects were observed during the study.<\/jats:p>\n                  <jats:p>CONCLUSIONS. This pilot study indicated that early postnatal intratracheal instillation of budesonide using surfactant as vehicle significantly improved the combined outcome of death or chronic lung disease in small premature infants without causing immediate adverse effects. The results are encouraging, and a large sample multicenter trial is warranted.<\/jats:p>","DOI":"10.1542\/peds.2007-1973","type":"journal-article","created":{"date-parts":[[2008,4,21]],"date-time":"2008-04-21T20:25:00Z","timestamp":1208809500000},"page":"e1310-e1318","source":"Crossref","is-referenced-by-count":162,"title":["Early Intratracheal Instillation of Budesonide Using Surfactant as a Vehicle to Prevent Chronic Lung Disease in Preterm Infants: A Pilot Study"],"prefix":"10.1542","volume":"121","author":[{"given":"Tsu F.","family":"Yeh","sequence":"first","affiliation":[{"name":"Department of Pediatrics, College of Medicine"},{"name":"Department of Pediatrics, John H. Stroger, Jr, Hospital of Cook County, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong C.","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien H.","family":"Chang","sequence":"additional","affiliation":[{"name":"Departments of Chemical Engineering"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien S.","family":"Wu","sequence":"additional","affiliation":[{"name":"Chemistry, National Cheng Kung University, Tainan, Taiwan"},{"name":"National Research Institute of Chinese Medicine, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai H.","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai C.","family":"Li","sequence":"additional","affiliation":[{"name":"Research Institute of Chinese Medicine, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma","family":"Pyati","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, John H. Stroger, Jr, Hospital of Cook County, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang H.","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Asian University, Wufeng, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,5,1]]},"reference":[{"key":"2021120908273007100_R1","doi-asserted-by":"crossref","unstructured":"Yeh TF, Lin YJ, Hsieh WS, et al. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics.\u20081997;100(4). Available at: www.pediatrics.org\/cgi\/content\/full\/100\/4\/e3","DOI":"10.1542\/peds.100.4.e3"},{"key":"2021120908273007100_R2","unstructured":"Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics.\u20081991;88(3):421\u2013427"},{"key":"2021120908273007100_R3","doi-asserted-by":"crossref","unstructured":"Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med.\u20081989;320(23):1505\u20131510","DOI":"10.1056\/NEJM198906083202301"},{"key":"2021120908273007100_R4","doi-asserted-by":"crossref","unstructured":"Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics.\u20082001;108(3):741\u2013748","DOI":"10.1542\/peds.108.3.741"},{"key":"2021120908273007100_R5","doi-asserted-by":"crossref","unstructured":"Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics.\u20081998;101(5). Available at: www.pediatrics.org\/cgi\/content\/full\/101\/5\/e7","DOI":"10.1542\/peds.101.5.e7"},{"key":"2021120908273007100_R6","unstructured":"Halliday HL, Ehrenkranz RA. Early postnatal (&lt;96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev.\u20082000;(2):CD001146"},{"key":"2021120908273007100_R7","doi-asserted-by":"crossref","unstructured":"Yeh TF, Lin YJ, Lin HC, et al. Outcome at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med.\u20082004;350(13):1304\u20131313","DOI":"10.1056\/NEJMoa032089"},{"key":"2021120908273007100_R8","doi-asserted-by":"crossref","unstructured":"Yeh TF, Torre JA, Rastogi A, Anyebuno MA, Pildes RS. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. J Pediatr.\u20081990;117(2 pt 1):273\u2013282","DOI":"10.1016\/S0022-3476(05)80547-5"},{"key":"2021120908273007100_R9","doi-asserted-by":"crossref","unstructured":"Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet.\u20081983;1(8338):1356\u20131358","DOI":"10.1016\/S0140-6736(83)92139-6"},{"key":"2021120908273007100_R10","doi-asserted-by":"crossref","unstructured":"Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics.\u20081985;75(1):106\u2013111","DOI":"10.1542\/peds.75.1.106"},{"key":"2021120908273007100_R11","doi-asserted-by":"crossref","unstructured":"Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight neonates. Cochrane Database Syst Rev.\u20082003;(1):CD002058","DOI":"10.1002\/14651858.CD002058"},{"key":"2021120908273007100_R12","doi-asserted-by":"crossref","unstructured":"Fok TF, Monkman S. Dolovich M, et al. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Ped Pulm.\u20081996;21(5):301\u2013309","DOI":"10.1002\/(SICI)1099-0496(199605)21:5<301::AID-PPUL5>3.0.CO;2-P"},{"key":"2021120908273007100_R13","doi-asserted-by":"crossref","unstructured":"Arnon S. Grigg J, Nikander K, Silverman M. Delivery of micronized budesonide suspension by metered dose inhaler and jet nebulizer into a neonatal ventilator circuit. Pediatr Pulmonol.\u20081992;13(3):172\u2013175","DOI":"10.1002\/ppul.1950130309"},{"key":"2021120908273007100_R14","doi-asserted-by":"crossref","unstructured":"Kova\u0301cs L, Davis GM, Faucher D, Papageorgiou A. Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. Acta Paediatr.\u20081998;87(7):792\u2013798","DOI":"10.1111\/j.1651-2227.1998.tb01749.x"},{"key":"2021120908273007100_R15","doi-asserted-by":"crossref","unstructured":"Grigg J, Arnon S, Jones T, Clarke A, Silverman M. Delivery of therapeutic aerosols to intubated babies. Arch Dis Child.\u20081992;67(1):25\u201330","DOI":"10.1136\/adc.67.1_Spec_No.25"},{"key":"2021120908273007100_R16","doi-asserted-by":"crossref","unstructured":"O'Callaghan C, Hardy J, Stammers J, Stephenson TJ, Hull D. Evaluation of techniques for delivery of steroids to lungs of neonates using a rabbit model. Arch Dis Child.\u20081992;67(1):20\u201324","DOI":"10.1136\/adc.67.1_Spec_No.20"},{"key":"2021120908273007100_R17","doi-asserted-by":"crossref","unstructured":"Cole CH, Colton T, Shah BL, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med.\u20081999;340(13):1005\u20131010","DOI":"10.1056\/NEJM199904013401304"},{"key":"2021120908273007100_R18","unstructured":"Lin YJ, Lin HC, Lin CH, Su BH, Yeh TF. Early endotracheal instillation of budesonide (B) for prevention of CLD in preterm infant with RDS-a double blind clinical trial. Ped Res.\u20082001;49(4):278A"},{"key":"2021120908273007100_R19","doi-asserted-by":"crossref","unstructured":"Fujiwara T, Chida S, Watabe Y, Maeta H, Morita T, Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet.\u20081980;1(8159):55\u201359","DOI":"10.1016\/S0140-6736(80)90489-4"},{"key":"2021120908273007100_R20","doi-asserted-by":"crossref","unstructured":"Ferrara TB, Hoekstra RE, Johnson P, Vernier RL. Localization of surfactant in neonatal lung after exogenous administration. J Pediatr.\u20081987;111(3):463\u2013466","DOI":"10.1016\/S0022-3476(87)80480-8"},{"key":"2021120908273007100_R21","unstructured":"Adamson AW. Introduction Marongoni convection. In: Adamson AW. Physical Chemistry of Surfaces. New York, NY: John Wiley and Sons; 1982:110"},{"key":"2021120908273007100_R22","doi-asserted-by":"crossref","unstructured":"Fajardo C, Levin D, Garcia M, Adrams D, Adamson I. Surfactant versus saline as a vehicle for corticosteroid delivery to the lungs of ventilated rabbits. Pediatr Res.\u20081998;43(4 pt 1):542\u2013547","DOI":"10.1203\/00006450-199804000-00018"},{"key":"2021120908273007100_R23","doi-asserted-by":"crossref","unstructured":"Kharasch VS, Sweeney TD, Fredberg J, et al. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis.\u20081991;144(4):909\u2013913","DOI":"10.1164\/ajrccm\/144.4.909"},{"key":"2021120908273007100_R24","unstructured":"Brattsand R, Thalen A, Roempke K, Kallstron L, Gruvstad E. Development of new glucocorticosteroids with a very high ratio between topical and systemic activities. Eur J Respir Dis.\u20081988;2(Suppl):122:62073"},{"key":"2021120908273007100_R25","doi-asserted-by":"crossref","unstructured":"Hvizdos KM, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs.\u20082000;60(5):1141\u20131178","DOI":"10.2165\/00003495-200060050-00010"},{"key":"2021120908273007100_R26","doi-asserted-by":"crossref","unstructured":"Johansson SA, Anderson KE, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. Eur J Chin Pharmacol.\u20081982;22(6):523\u2013529","DOI":"10.1007\/BF00609625"},{"key":"2021120908273007100_R27","doi-asserted-by":"crossref","unstructured":"Ryrfeldt A, Edsba\u0308cker S, Pauwels R. Kinetics of the epimeric glucocorticoid budesonide. Clin Pharmacol Ther.\u20081984;35(4):525\u2013530","DOI":"10.1038\/clpt.1984.71"},{"key":"2021120908273007100_R28","unstructured":"Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons; 1973:23\u201335"},{"key":"2021120908273007100_R29","doi-asserted-by":"crossref","unstructured":"Palmer, D, Schurch, S, Belik J. Effect of budesonide and salbutamol on surfactant properties. J Appl Physiol.\u20082000;89(3):884\u2013890","DOI":"10.1152\/jappl.2000.89.3.884"},{"key":"2021120908273007100_R30","unstructured":"Chang DH, Chang CH, Lin YJ, Yeh TF. Influence of budesonide (B) on the dynamic surface tension behavior of surfactant (survanta) (s) at pulsating air\u2013liquid interface. Ped Res.\u20082002;51(4):346A"},{"key":"2021120908273007100_R31","unstructured":"Bisgaard H, Munch E, Nikander K. Equrpotency of budesonide administration from a MDI and from a nebulized suspension. Eur Reopir J.\u20081989;2(suppl 8):769S"},{"key":"2021120908273007100_R32","doi-asserted-by":"crossref","unstructured":"Schouten-Van Meeteren NYN, Rietveld A, Moolenaar AJ, Van Bel F. Influence of perinatal condition on C-reactive protein production. J Pediatr.\u20081992;120(4 pt 1):621\u2013626","DOI":"10.1016\/S0022-3476(05)82493-X"},{"key":"2021120908273007100_R33","doi-asserted-by":"crossref","unstructured":"Wang Y, Tan Y, Moellmann H, Hochhaus G. Simultaneous quantification of budesonide and its two metabolites, 6 B-hydroxyl budesonide and 16 \u03b1\u2013hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry. Biomed Chromatogr.\u20082003;17:158\u2013164","DOI":"10.1002\/bmc.233"},{"key":"2021120908273007100_R34","doi-asserted-by":"crossref","unstructured":"Nimmo AJ, Carstairs JR, Patole SK, Whitehall J, Davidson K, Vink R. Intratracheal administration of glucocorticoids using surfactant as a vehicle. Clin Exper Pharmcol Physiology.\u20082002;29(8):661\u2013665","DOI":"10.1046\/j.1440-1681.2002.03712.x"},{"key":"2021120908273007100_R35","doi-asserted-by":"crossref","unstructured":"Chen CM, Fang CL, Chang CH. Surfactant and corticosteroid effects on lung function in a rat model of acute lung injury. Crit Care Med.\u20082001;29(11):2169\u20132175","DOI":"10.1097\/00003246-200111000-00020"},{"key":"2021120908273007100_R36","unstructured":"Patole SK, Mohan MS, Jog SM, Muller R, Whitehall JS. Prophylactic intratracheal budesonide in preterm neonates at risk for chronic lung disease (CLD)-a pilot study. Presented at the Annual Conference of the Perinatal Society of Australia and New Zealand; March 2\u20133, 2001; Canberra, Australia; No. 1590"},{"key":"2021120908273007100_R37","doi-asserted-by":"crossref","unstructured":"Wu JM, Yeh TF, Wang JY, et al. The role of pulmonary inflammation in the development of pulmonary hypertension in newborn with meconium aspiration syndrome (MAS). Ped Pul.\u20081999;18(suppl):205\u2013208","DOI":"10.1002\/(SICI)1099-0496(1999)27:18+<205::AID-PPUL66>3.0.CO;2-0"},{"key":"2021120908273007100_R38","unstructured":"Vogt BA, Avner ED. The kidney and urinary tract. In: Fanaroff AA, Martin R, eds. Neonatal-Perinatal Medicine. 7th ed. Vol 2. St Louis, MO: Mosby; 2002:1526\u20131527"},{"key":"2021120908273007100_R39","doi-asserted-by":"crossref","unstructured":"Van Den Bosch, JMM, Westermann CJJ, Aumann J, Edba\u0308cker S, Tonnesson M, Selroos O. Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharm Drug Dispos.\u20081993;14(5):455\u2013459","DOI":"10.1002\/bdd.2510140511"},{"key":"2021120908273007100_R40","doi-asserted-by":"crossref","unstructured":"Plam S, Wiedmann TS. Note: dissolution of aerosol particles of buesonide in Survanta TM, a model lung surfactant. J Pharmaceutical Sci.\u20082001;90(1):98\u2013104","DOI":"10.1002\/1520-6017(200101)90:1<98::AID-JPS11>3.3.CO;2-X"},{"key":"2021120908273007100_R41","doi-asserted-by":"crossref","unstructured":"Wiedmann TS, Bhatia R, Wattenberg LW. Drug solubilization in lung surfactant. J Control Release.\u20082000;65(1\u20132):43\u201347","DOI":"10.1016\/S0168-3659(99)00230-8"},{"key":"2021120908273007100_R42","unstructured":"Miller-Larsson A, Mattsson H, Hjertberg E, Dahlba\u0308ck M, Tunke A, Brattsand R. Reversible fatty acid conjugation of budesonide: novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos.\u20081998;26(7):623\u2013630"},{"key":"2021120908273007100_R43","doi-asserted-by":"crossref","unstructured":"Borchard G, Cassara ML, Roemele, PEH, Florea BI, Junginer HE. Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (calu-3). J Pharm Sci.\u20082002;91(6):1561\u20131566","DOI":"10.1002\/jps.10151"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/5\/e1310\/1175472\/zpe005080e1310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/5\/e1310\/1175472\/zpe005080e1310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T21:53:00Z","timestamp":1639086780000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/5\/e1310\/73470\/Early-Intratracheal-Instillation-of-Budesonide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,1]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2008,5,1]]},"published-print":{"date-parts":[[2008,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-1973","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1109095.561482","asserted-by":"object"}]},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,1]]}}}